Skip to main content
Have a personal or library account? Click to login
A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a metaanalysis Cover

A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a metaanalysis

Radiology and Oncology
Volume 47 (2013): Issue 2 (June 2013)
By: ,  ,   and    
Open Access
|May 2013
References

References

  1. 1. Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatment.2007;1416-31.
    Open DOISearch in Google Scholar
  2. 2. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.1984;521-7.
    Open DOISearch in Google Scholar
  3. 3. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis.2001;S9-15.
    Open DOISearch in Google Scholar
  4. 4. Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, et al. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what’s genetics got to do with it?2005;1009-30.
    Search in Google Scholar
  5. 5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network.2001;127-37.
    Open DOISearch in Google Scholar
  6. 6. Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N, Novakovic S, Ocvirk J. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis.2011;285-91.
    Open DOISearch in Google Scholar
  7. 7. Jia Y, Lacouture ME, Su X, Wu S. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.2009;211-7.
    Search in Google Scholar
  8. 8. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.2007;610-21.
    Open DOISearch in Google Scholar
  9. 9. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.2009;16-26.
    Open DOISearch in Google Scholar
  10. 10. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.2005;345-56.
    Open DOISearch in Google Scholar
  11. 11. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab.2007;175-82.
    Open DOISearch in Google Scholar
  12. 12. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.2005;1425-33.
    Open DOISearch in Google Scholar
  13. 13. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.2006;657-70.
    Open DOISearch in Google Scholar
  14. 14. Ehmann LM, Ruzicka T, Wollenberg A. Cutaneous side-effects of EGFR inhibitors and their management.2011;1-3.
    Search in Google Scholar
  15. 15. Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.2010;47-53.
    Open DOISearch in Google Scholar
  16. 16. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.2010;1351-7.
    Open DOISearch in Google Scholar
  17. 17. Oslo A, Mateurs C, Soria JC, Smith A. Cutaneous side effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.2009;515-21.
    Open DOISearch in Google Scholar
  18. 18. Lacouture M. The growing importance of skin toxicity in EGFR inhibitor therapy.2009;194-6.
    Search in Google Scholar
  19. 19. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies.2005;491-500.
    Open DOISearch in Google Scholar
  20. 20. Peeters M, Price T, Van Laethem JL. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?2009;29-39.
    Search in Google Scholar
  21. 21. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?2005;5235-46.
    Search in Google Scholar
  22. 22. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation.2008;48-54.
    Open DOISearch in Google Scholar
  23. 23. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.2004;1201-8.
    Open DOISearch in Google Scholar
  24. 24. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.2007;3913-21.
    Open DOISearch in Google Scholar
  25. 25. Kovac V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Minireview.2004;334˝1-40.
    Search in Google Scholar
  26. 26. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.2011;524-35.
    Open DOISearch in Google Scholar
  27. 27. Wollenberg A, Moosmann N, Klein E, Katzer K. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.2008;790-2.
    Open DOISearch in Google Scholar
  28. 28. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.2010;509-22.
    Open DOISearch in Google Scholar
  29. 29. Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.2010;94-8.
    Open DOISearch in Google Scholar
  30. 30. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.2008;142-9.
    Open DOISearch in Google Scholar
  31. 31. Lacouture ME. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.2007;S17-26.
    Open DOISearch in Google Scholar
  32. 32. Segaert S, Van Cutsem E. Clinical management of EGFRI dermatologic toxicities: the European perspective.2007;22-6.
    Search in Google Scholar
  33. 33. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.2007;845-51.
    Open DOISearch in Google Scholar
  34. 34. Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.2005;599-606.
    Open DOISearch in Google Scholar
  35. 35. Bernier J, Russi EG, Homey B, Merlano MC, Mesia R, Peyrade F, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.2011;2191-200.
    Open DOISearch in Google Scholar
  36. 36. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.2007;317-26.
    Open DOISearch in Google Scholar
  37. 37. Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinibinduced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.2009;106-11.
    Open DOISearch in Google Scholar
  38. 38. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.2011;343-51.
    Open DOISearch in Google Scholar
  39. 39. Jatoi A. Sunshine and rash: testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash.2007;198-202.
    Open DOISearch in Google Scholar
  40. 40. Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).2010;1016-22.
    Open DOISearch in Google Scholar
  41. 41. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).2008;847-53.
    Open DOISearch in Google Scholar
  42. 42. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).2011;1601-7.
    Open DOISearch in Google Scholar
  43. 43. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.2007;5390-6.
    Open DOISearch in Google Scholar
  44. 44. Deplanque G, Chavaillon J, Vergnenegre A, Falchero L. CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinibinduced folliculitis in non-small cell lung cancer patients [Abstract].2010;Abstract 9019.
    Open DOISearch in Google Scholar
  45. 45. Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.2009;614-20.
    Open DOISearch in Google Scholar
  46. 46. Fernandez-Guarino M, Perez Garcia B, Aldanondo Fernandez de la Mora I, Garcia-Millan C, Garrido Lopez P, Jaen Olasolo P. [Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines]. [Spanish].2006;503-8.
    Search in Google Scholar
  47. 47. Micantonio T, Fargnoli MC, Ricevuto E, Ficorella C, Marchetti P, Peris K. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy.2005;1173-4.
    Open DOISearch in Google Scholar
  48. 48. Molinari E, De Quatrebarbes J, Andre T, Aractingi S. Cetuximab-induced acne.2005;330-3.
    Open DOISearch in Google Scholar
  49. 49. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases.2001;105-10.
    Open DOISearch in Google Scholar
  50. 50. Mitchell E, Lacouture M, Shearer H, Iannotti N. Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC) [Abstract].2009;Abstract CRA4027.
    Open DOISearch in Google Scholar
  51. 51. Hedges LV, Olkin I.Orlando: Academic Press; 1985.
    Search in Google Scholar
  52. 52. Laird NM, Ware JH. Random-effects models for longitudinal data.1982;963-74.
    Open DOISearch in Google Scholar
  53. 53. Luu M, Lai SE, Patel J, Guitart J, Lacouture ME. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib.2007;42-5.
    Open DOISearch in Google Scholar
  54. 54. Segaert S, Simonart T. The epidermal vitamin D system and innate immunity: some more light shed on this unique photoendocrine system?2008;7-11.
    Search in Google Scholar
  55. 55. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors.2009;107-19.
    Open DOISearch in Google Scholar
  56. 56. Perez-Soler R, Zou Y, Li T, Ling Y. Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib (E) in human skin keratinocytes whereas Vit K3 exerts a protective effect: implications for the management of the skin rash [Abstract].2007;Abstract 9124.
    Open DOISearch in Google Scholar
  57. 57. Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin [Abstract].2006;Abstract 3036.
    Open DOISearch in Google Scholar
  58. 58. Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 creme.2008;215-24.
    Open DOISearch in Google Scholar
  59. 59. Ocvirk J, Rebersek M. Topical application of vitamin K1 cream for cetuximabrelated skin toxicities [Abstract].2009;Abstract PD-0021.
    Search in Google Scholar
  60. 60. Pinto C, Barone C, Martoni A, Di Tullio P, Di Fabio F, Cassano A. Vitamin K1 cream in the management of skin rash during anti-EGFR monocloncal antibody (mAb) treatment in patients with metastatic cancer: first analysis of an observational Italian study [Abstract].2011;Abstract 594.
    Open DOISearch in Google Scholar
  61. 61. Ocvirk J, Rebersek M, Boc M, Mesti T, Ebert M. Prophylactic use of K1 cream for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC) [Abstract].2010;Abstract e14011.
    Open DOISearch in Google Scholar
  62. 62. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.2011;1079-95.
    Open DOISearch in Google Scholar
  63. 63. Potthoff K, Hassel JC, Wollenberg A. Therapie und prophylaxe EGFRinhibitor- induzierter hautreaktionen.2010;191-8.
    Search in Google Scholar
  64. 64. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.2010;4706-13.
    Open DOISearch in Google Scholar
  65. 65. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.2010;4697-705.
    Open DOISearch in Google Scholar
  66. 66. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.2009;663-71.
    Open DOISearch in Google Scholar
  67. 67. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.2011;2011-9.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/raon-2013-0014 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 166 - 175
Published on: May 21, 2013
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
acne-like skin rash,
cetuximab,
antibiotics,
erlotinib,
gefitinib,
panitumumab,
vitamin K
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2013 Janja Ocvirk, Steffen Heeger, Philip McCloud, Ralf-Dieter Hofheinz, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 47 (2013): Issue 2 (June 2013)
Previous article
Next article